May 8th 2024
A phase 3 study evaluating uproleselan in relapsed/refractory acute myeloid leukemia missed its primary end point of overall survival.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Tisagenlecleucel Maintains Efficacy in Updated Results of Global ALL Trial
September 14th 2017Updated findings from the registration trial of the first FDA-approved CAR T-cell therapy showed that 83% of patients with acute lymphoblastic lymphoma achieved complete remission with complete or incomplete hematologic recovery, as reported at the 2017 Society of Hematologic Oncology Annual Meeting.<br />
Read More
Study Finds Hospice Not Being Used Optimally for End-of-Life AML Care
August 28th 2017Results from a recent retrospective study published in the<em> Journal of Clinical Oncology</em><sup> </sup>revealed hospice enrollment is low and use of aggressive treatment is high for elderly patients with acute myeloid leukemia.
Read More
Crenolanib Shows Promise as TKIs Move to Forefront of AML Treatment, Expert Says
August 28th 2017Eunice Wang, MD, discusses a study examining the biology of newly diagnosed patients with <em>FLT3</em>-positive acute myeloid leukemia who achieved a response to the FLT3 TKI crenolanib combined with chemotherapy.
Read More
The First Targeted Therapy Directed at FLT3 Mutations in Patients With AML
August 10th 2017Mutations in FLT3 have long been recognized in a portion of patients with acute myeloid leukemia. Yet it took more than 15 years until an agent targeting FLT3 mutations came to fruition with the FDA approval of midostaurin in April 2017, marking about 40 years since the last new agent was approved to treat patients with AML.
Read More
CPX-351 Approved by FDA for 2 Types of AML
August 3rd 2017CPX-351 (Vyxeos), a fixed-combination of daunorubicin and cytarabine, has been approved by the FDA for adult patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), based on an improvement in overall survival (OS) in a phase III study.
Read More
Enasidenib Approved by FDA for IDH2-Mutated AML
August 1st 2017Enasidenib (Idhifa) has been approved by the FDA as a treatment for patients with relapsed or refractory <em>IDH2</em>-mutated acute myeloid leukemia (AML), based on findings from a phase I/II study. A companion diagnostic, the RealTime IDH2 Assay, was also approved for the detection of the <em>IDH2</em> mutation.
Read More
Venetoclax Granted Breakthrough Therapy Designation by FDA for AML Subpopulation
July 31st 2017The FDA has granted breakthrough therapy designation to venetoclax (Venclexta) for use in combination with low dose cytarabine (LDAC) in treatment-naïve elderly patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, according to Roche, which is codeveloping the BCL-2 inhibitor with AbbVie.
Read More
Midostaurin Granted Recommendation for EU Approval in AML
July 24th 2017Midostaurin (Rydapt) has been recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to treat adults with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation–positive.
Read More
ODAC Recommends Approval of Tisagenlecleucel for Relapsed/Refractory Pediatric ALL
July 13th 2017The Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.
Read More
Gemtuzumab Ozogamicin Recommended for Approval by ODAC for Newly Diagnosed AML
July 12th 2017In a 6-1 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in favor of approving gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia.
Read More
Blinatumomab Granted Full Approval by the FDA for B-cell Precursor ALL
July 12th 2017Blinatumomab (Blincyto) has been granted a full approval by the FDA as a treatment for adults and children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, regardless of Philadelphia chromosome status.
Read More
Phase I Results for Enasidenib in AML
June 7th 2017Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutant <em>IDH-2</em> relapsed or refractory acute myeloid leukemia (AML) during the 2017 ASCO Annual Meeting.
Watch
Midostaurin Approved by FDA for AML
April 28th 2017Midostaurin (Rydapt) has been approved by the FDA for the treatment of adult patients with newly diagnosed <em>FLT3</em>-positive acute myeloid leukemia (AML) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Read More
New Conditioning Regimens May Prevent Blood Cancer Relapses
April 14th 2017Patients with hematologic malignancies who receive a hematopoietic stem cell transplant (HSCT) still risk treatment failure through relapse. As part of a conditioning regimen prior to allogenic HSCT, strategies are emerging to improve HSCT outcomes by reducing the risk of relapse. Several of these conditioning regimens were reviewed during a satellite symposium to the 2017 BMT Tandem Meetings.
Read More
Finding a Quick, Durable Therapy for Elderly Patients With AML is the Holy Grail, Expert Says
April 12th 2017Andrew Wei, MBBS, PhD, discusses a study which explored the safety and efficacy of the novel BCL-2 inhibitor venetoclax in combination with low-dose cytarabine chemotherapy for treatment-naïve patients over the age of 65 with AML.
Read More
Exploiting DNA Repair Deficiency in IDH-Mutant Brain Tumors Likely an Improved Treatment Strategy
April 6th 2017Mutations in isocitrate dehydrogenase 1 and 2 (<em>IDH1/2</em>) are not the mutations commonly found in cancer cells, according to a presentation from the 2017 AACR Annual Meeting.
Read More
Exploring Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With AML
April 6th 2017Sudipto Mukherjee, MD, assistant staff, Gaussig Cancer Institute, Cleveland Clinic, discusses a study exploring eltrombopag to enhance platelet count recovery in elderly patients with acute myeloid leukemia (AML).
Watch
Immune Checkpoint Approaches in AML and MDS: A Next Frontier?
March 7th 2017The researchers discuss the rationale for checkpoint-based therapies including antibodies to PD-1/PD-L1 and CTLA-4, an overview of clinical experience with these agents, and future considerations and combinations of these agents.
Read More
Early Signs of Activity From Lirilumab/Azacytidine Combo in Heavily Pretreated AML
December 6th 2016The combination of lirilumab and azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia (AML), according to phase Ib/II findings presented at the 2016 ASH Annual Meeting.
Read More
Vadastuximab Talirine Shows Early Signs of Efficacy in Patients With AML
December 5th 2016With treatment for newly diagnosed acute myeloid leukemia remaining essentially unchanged over the last 4 decades, researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for these patients.
Read More